https://www.thepharmaletter.com/article/iterum-hopeful-despite-phase-iii-miss-for-sulopenem

https://www.empr.com/home/news/drugs-in-the-pipeline/novel-antibiotic-sulopenem-misses-primary-end-point-in-ciai-trial/

http://www.cidrap.umn.edu/news-perspective/2019/12/stewardship-resistance-scan-dec-12-2019

https://www.contagionlive.com/news/sulopenem-narrowly-misses-primary-end-point-in-phase-3-ciai-study

https://www.contagionlive.com/news/the-id-pipeline-fda-activity-from-the-week-of-december-8-2019